Manages exogenous obesity. ANDA 205008, held by Nuvo Pharm. Phentermine Hydrochloride.
As of Nov 16, 2026, ANDA 205008 (Phentermine Hydrochloride), held by Nuvo Pharm, was first approved by FDA on Sep 25, 2014, with 1 approved supplement and 0 published complete response letters.
Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m 2, or ≥ 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phentermine Hydrochloride37.5MG · tablet;oral | Phentermine Hydrochloride | Rx |
| May 31, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 25, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters